According to Zhito Finance APP, *ST Longjin (002750.SZ) announced that the company's holding subsidiary yunnan Longjin Kangyou biomedical Co., Ltd. (referred to as 'Longjin Kangyou') recently received the 'Pharmaceutical Registration Certificate' for sildenafil citrate oral dispersible tablets (certificate number: 2024S02682) approved by the National Medical Products Administration. Sildenafil is the world's first approved selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction, with advantages such as rapid action and definite efficacy, making it the most widely used first-line medication for erectile dysfunction in domestic clinical applications.